BioCryst inks at-market issuance sales agreement for up to $70 million

McNicoll, Lewis & Vlak helps sell shares to public through offering

By Devika Patel

Knoxville, Tenn., July 1 - BioCryst Pharmaceuticals, Inc. could raise up to $70 million in a public sale of its stock via agent McNicoll, Lewis & Vlak LLC, according to an 8-K filed Friday with the Securities and Exchange Commission. The at-market issuance sales agreement was negotiated June 28.

The agent will sell the company's common stock on a commercially reasonable efforts basis.

Based in Birmingham, Ala., BioCryst develops small-molecule pharmaceuticals for the prevention, treatment and control of cancer, cardiovascular diseases and viral infections.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.